Cargando…
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM
INTRODUCTION: The immunosuppressive tumor microenvironment (TME) is a major barrier to the efficacy of chimeric antigen receptor T cells (CAR-T cells) in glioblastoma (GBM). Transgenic expression of IL15 is one attractive strategy to modulate the TME. However, at present, it is unclear if IL15 could...
Autores principales: | Zannikou, Markella, Duffy, Joseph T, Levine, Rebecca N, Seblani, Maggie, Liu, Qianli, Presser, Aaron, Arrieta, Victor A, Chen, Christopher J, Sonabend, Adam M, Horbinski, Craig M, Lee-Chang, Catalina, Miska, Jason, Lesniak, Maciej S, Gottschalk, Stephen, Balyasnikova, Irina V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923337/ https://www.ncbi.nlm.nih.gov/pubmed/36759014 http://dx.doi.org/10.1136/jitc-2022-006239 |
Ejemplares similares
-
CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023) -
NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021) -
Serpin B9 controls tumor cell killing by CAR T cells
por: Kimman, Thomas, et al.
Publicado: (2023) -
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer
por: Nalawade, Saisha A, et al.
Publicado: (2021) -
Automated, scaled, transposon-based production of CAR T cells
por: Lock, Dominik, et al.
Publicado: (2022)